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Tables and Figures
Table 1 Characteristics of the randomised controlled trials (RCTs) that are included in this 
review
Table 2 Effects sizes from meta-analysis of primary and secondary outcomes; end of 
treatment; from all trials using fixed effects models, where at least two trials provided data 
that could be included 
Table 3
Summary effect sizes for trials at low risk of bias, at end of treatment, where at least two 
trials reported the outcome of interest. Fixed effects models 
Figure 1. Flow diagram showing selection of studies
Figure 2 Risk of Bias
Figure 3. Forest plot, mRS (0-2) at end of treatment
Figure 4. Forest plot, disability at end of treatment
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Objective: To determine whether fluoxetine, at any dose, given within the first year after 
stroke to patients who did not have to have mood disorders at randomisation led to a 
reduction in disability, dependency, neurological deficits and fatigue; improved motor 
function, mood, and cognition at the end of treatment and follow-up, with the same number 
or fewer adverse effects. 
Methods: Searches in July 2018 included several databases, trials registers, reference lists, 
contact with experts. We excluded RCTs requiring patients to have mood disorder at 
randomisation. Co-primary outcomes were dependence and disability. Dichotomous data 
were synthesised using risk ratios (RR) and continuous data using standardised mean 
differences (SMD). Quality was appraised using Cochrane risk of bias methods. Sensitivity 
analyses explored influence of study quality.
Results: The searches identified 3412 references of which 491 full texts were assessed for 
eligibility. Six new completed RCTs (n=3710) ere eligible, making a total of 13 trials 
(n=4145).  There was no difference in the proportion independent at the end of treatment (3 
trials, n=3249, 36·6% fluoxetine vs 36·7% control; RR 1·00, 95% confidence interval 0·91 to 
1.09, p=0·99, I2 78%) and no difference in disability (7 trials n=3404, SMD 0·05, -0·02 to 
0·12 p=0·15, I2=81%). Fluoxetine was associated with better neurological scores and less 
depression but more seizures. Among the four (n=3283) high quality RCTs, the only 
difference between groups was lower depression scores with fluoxetine. 
Conclusion: Fluoxetine does not reduce disability and dependency after stroke. It improves 
depression scores but increases seizures. Ongoing RCTs will determine its effects in stroke 
vary depending on ethnicity, background treatment and other factors.
Classification of evidence: meta-analysis
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Background and purpose
Worldwide, stroke is the second leading cause of death, the third leading cause of disability 
[1], and results in 6.5 million years being lived with disability [2].  Fluoxetine is a selective 
serotonin reuptake inhibitor (SSRI) which has been used for many years to treat mood 
disorders, including post-stroke depression. A 2010 systematic review suggested that 
fluoxetine might improve recovery in stroke patients without depression [3]. In 2011, a 
randomised controlled trial (RCT) recruiting 118 patients with hemiparesis due to recent (5-
10 days previously) ischaemic stroke reported better motor recovery and reduced dependency 
with 3 months treatment with fluoxetine [4], possibly by promotion of neurogenesis [5], 
neuroprotection [6], modulation of cerebral motor activity [7] and prevention of depression. 
A 2012 Cochrane systematic review of SSRIs for stroke recovery suggested that fluoxetine 
reduced disability after stroke even in patients without depression, but poor methodological 
trial quality probably introduced bias [8]. Since then one large (n=3127) trial of fluoxetine for 
stroke recovery has been published [9]. Meta-analyses should be updated as soon as there are 
new studies that might change the conclusions of the review. 
Objective
We sought to determine whether fluoxetine, at any dose, given within the first year after 
stroke to patients who did not have to have mood disorders at randomisation, reduced 
disability, dependency, neurological deficits and fatigue, and improved motor function, 
mood, and cognition at the end of treatment and follow-up, with the same number or fewer 
adverse effects. 
Methods 
Protocol and registration
Page 5 of 54 International Journal of Stroke
For Review Only
We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analysis). Data supporting this review are available from the corresponding author. 
We did not register the current review on PROSPERO as we used the same methods as the 
2012 Cochrane review, except for a) including only fluoxetine trials b) excluding trials 
requiring patients to have mood disorders at randomisation, c) simplifying our sensitivity 
analyses by excluding trials at high or unclear risk of bias in at least one domain rather than 
considering each domain individually, d) excluding trials comparing fluoxetine plus another 
‘active treatment’ versus the ‘active treatment’ and e) defining incomplete outcome data 
reporting as systematic differences in withdrawals between groups rather than a total of >5%. 
These five criteria (a-e) were agreed prior to study selection and data extraction. 
After study selection and data extraction, but prior to analyses, we decided to report the 
proportion independent (modified Rankin score, mRS 0-2) rather than the proportion 
dependent (mRS 3-5).  
Random effects models were used in the 2012 Cochrane review because we assumed that the 
included studies would represent a random sample of the effect sizes that could be observed. 
As the large Fluoxetine or Control Under Supervision (FOCUS) trial had systematically 
different results from the smaller trials, a random effects model would have given 
disproportionate weight to smaller studies [10]. Therefore we report fixed effects models. We 
performed sensitivity analyses using random effects models and report any major differences 
between the two. 
Eligibility criteria
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Participants: stroke in the previous year. Stroke was defined as sudden-onset focal 
neurological disturbance, assumed to be vascular in origin, and lasting more than 24 hours 
[11]. We excluded trials requiring patients to have a mood disorder at randomisation.   
Types of intervention: any dose of fluoxetine, any mode of delivery, given for any duration. 
Comparator arm was usual care or a placebo. We excluded studies comparing fluoxetine plus 
another 'active treatment' versus ‘active treatment' alone, because of possible interactions.  
Outcomes We pre-specified two co-primary outcomes: independence or disability at the end 
of treatment (using any measure). Improvements in disability (performance of activities of 
daily living) could be important to patients even without a change in overall dependence.
Secondary outcomes: independence and disability at the end of follow-up. Neurological 
score, depression, anxiety, cognition, quality of life, fatigue, healthcare costs, death, motor 
scores, adverse events (at the end of treatment and/or at the end of follow-up), ‘leaving the 
trial before scheduled follow-up’ which included any reason other than death for missing 
outcome data.  
Report characteristics: We included all reports irrespective of year of publication, language 
and publication status. Where necessary we sought unpublished data from authors.
Information sources
Searches were performed:  
Cochrane Stroke Group Trials Register (17 July 2018); 
* Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2018, 
Issue 6); 
* MEDLINE Ovid (from 1948 to 17 July 2018); 
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* Embase Ovid (from 1980 to 17 July 2018); 
* CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; from 1982 to 
17 July 2018); 
* AMED (Allied and Complementary Medicine; from 1985 to 17 July 2018); 
* PsycINFO Ovid (from 1967 to 17 July 2018). 
* US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov 
(www.clinicaltrials.gov); and * World Health Organization International Clinical Trials 
Registry Platform (apps.who.int/trialsearch) on 26th June 2018. 
We screened reference lists from review articles and included papers. We contacted experts 
to identify additional studies. 
Study selection
Duplicate references were removed using COVIDENCE software (www.covidence.org). 
Titles and abstracts were scrutinised by two authors. Obviously irrelevant articles were 
excluded.
Full texts of potentially relevant articles were retrieved and inclusion criteria applied by two 
authors. A third author was involved if there was disagreement. We included studies meeting 
our criteria.  
Data collection process
Two reviewers independently extracted data from the new trials using COVIDENCE.  We 
contacted the authors if data were missing or required in a different format.  
Data items 
Continuous and dichotomous data were extracted. If trials reported the same number of 
patients at beginning and end, we assumed there had been no deaths. If there was no 
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description of how adverse events were recorded, we included any available data on adverse 
events, but did not assume the absence of serious adverse events unless the authors had 
explicitly reported this.  If there was a different number of patients at the end of the trial, we 
extracted data on deaths and drop-outs for other reasons. The denominator was the number of 
patients for whom a particular outcome was available. 
Risk of bias of individual studies
Two authors using the same criteria as previously [8].  We included allocation (selection 
bias), blinding (performance bias and detection bias), incomplete outcome data (systematic 
differences between groups in withdrawals from a study), selective reporting and other 
potential sources of bias.  
Pre-specified sensitivity analyses 
Sensitivity analyses explored the influence of bias by excluding studies with unclear or high 
risk of bias across one or more key domains [10]. 
Summary measures and synthesis of results
Risk ratios (RRs) were used for dichotomous data and for ordinal scales with an established 
cut-point. Standardised mean differences (SMD) were used for continuous data and ordinal 
scales with no standard cut-point.  We pre-specified our interpretation of SMD: 0.2 represents 
a small effect, 0.5 a moderate effect, and 0.8 a large effect [10]. 
One trial [12] reported medians, interquartile ranges and ranges. We estimated the mean and 
standard deviation (SD) using the best available method [13]. 
Risk of bias across studies
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Funnel plot was used to investigate publication bias. When available, we scrutinised 
protocols to investigate selective reporting. 
Subgroup analyses  
Because fluoxetine may be more effective when given earlier after stroke, we aimed to 
explore the influence of time since stroke at recruitment on our primary outcome by 
categorising studies as less than three months, three to six months, six to nine months, nine to 
12 months.  
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Results
From the database searches, we identified 3412 references, removed 426 duplicates, screened 
2988 references, and assessed 500 full texts for eligibility (figure 1).  Three published papers 
had the same grant number [14-16], very similar inclusion criteria and recruited patients from 
the same hospital during overlapping time periods; one appeared to be the three year follow-
up data [16] from one of the earlier publications [15]. Thus we included the publication with 
the largest number of patients reporting our pre-specified outcomes [15] and categorised the 
other two [14,16] as ‘awaiting assessment’ pending further information. We identified three 
further new eligible trials from the database searches [12, 17, 18] and one by contact with 
experts [19]. We also included FOCUS [9]. 
These six new trials (n=3710) [9, 12, 15, 17-19] were added to seven eligible trials [4, 20-25] 
(n=435) identified in the 2012 Cochrane review (total 13 completed trials, n=4145, table 1). 
One further registered trial was withdrawn because it recruited no patients [27].
Several ongoing RCTs together aim to recruit about 3775 patients (appendix). 
Risk of Bias
There were four high quality trials (n=3283) with a low risk of bias across important quality 
criteria [4, 9,12,18] (figure 2).  One terminated early having recruited 6 patients, and reported 
no deaths [18].  The Funnel plot for disability showed no clear evidence of publication bias 
(available on request).
Results of studies and synthesis of results
Co-primary outcomes: independence and disability at end of treatment (figures 3 and 4). 
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Three trials (n=3249) reported independence. Fixed effects meta-analysis found no difference 
in the proportion independent (36.6% in fluoxetine vs 36.7% control; RR 1.00, 95% 
confidence interval 0.91 to 1.09, p=0.99, I2 78%) and no difference in disability (7 trials 
n=3404, SMD 0.05 (-0.02 to 0.12) p=0.15, I2=81%). 
Two other trials [19, 26] reported improvements in mRS in the fluoxetine group but the data 
were in a format that could not be used in the meta-analysis and the authors did not respond 
to our requests for clarification.  
Random effects models demonstrated a small, but statistically significant benefit of 
fluoxetine on disability (SMD 0.34, 0.04 to 0.64, p=0.03, I2=81%); and a higher RR (RR 1.87 
(0.74 to 4.56; p=0.19, I2=78%) of being independent than the fixed effects models because of 
the greater weight given to smaller positive trials.
Secondary outcomes at end of treatment: summary effect sizes (table 2) 
Fluoxetine was associated with better neurological scores (8 trials, n=803, SMD -0.28 (-0.42 
to -0.14) p=<0.001, I2 77%), better depression scores (6 trials n=3113 SMD -0.16 (-0.23 to -
0.09) p<0.0001, I2 92%), fewer diagnoses of depression (2 trials n=3194 RR 0.77 (0.65 to 
0.90) p=0.001, I2=53%) but more seizures (7 trials n=3815, 3.9% vs 2.6% RR 1.49 (1.05 to 
2.11) p=0.03, I2=0). Random effects models gave broadly similar results. FOCUS identified a 
slight excess of bone fractures in the fluoxetine group which was statistically significant. No 
other trial reported fractures. 
End of follow-up 
Two trials (n=2924) reported disability at end of follow up: SMD was 0.11 (-0.17 to 0.40) 
p=0.45, I2=85% (fixed effects).
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Sensitivity analyses: high quality trials only (table 3), fixed effects 
Fixed effects models found a small, but statistically significant effect on depression scores at 
end of treatment (2 trials, n=2861, -0.11 (-0.19 to -0.04) p=0.002, I2=69%). Random effects 
found a slightly larger effect size for depression which was not statistically significant (-0.23 
(-0.56 to 0.10) p=0.07, I2 61%).
Subgroup analyses
We did not perform subgroup analyses because all trials except two (n=68) recruited patients 
within three months of stroke onset.
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Discussion
This systematic review of fluoxetine for stroke recovery identified 14 trials recruiting more 
than 4000 patients of which four (n=3283) were of high methodological quality. 
There were no differences between groups for the co-primary outcomes of dependency and 
disability. Fluoxetine was associated with better neurological scores at the end of treatment, 
better depression scores and fewer diagnoses of depression, although the effect sizes were all 
small and there was substantial heterogeneity. There was a higher risk of seizures with 
fluoxetine. However, when only high quality trials were considered, the only statistically 
significant difference between groups was better (lower) depression scores at the end of 
treatment.  
We used fixed effect models as these give appropriate weight to larger trials. The sensitivity 
analysis using random effects models found a spuriously large benefit of fluoxetine on 
independence (RR 1.87) because of the disproportionate weight given to smaller trials. Fixed 
and random effect models produced only slightly different effect sizes for depression scores. 
Previous meta-analyses suggested that fluoxetine might reduce dependency and disability if 
given early after stroke [3, 8, 28]. This current meta-analysis, which included many more 
patients than previous reviews, has not confirmed these promising effects. Although one of 
the reviews [28] strongly recommended fluoxetine to promote neurological recovery, this 
recommendation was based on the results of just four reports [4, 14, 15, 22], only one of 
which was high quality [4].   
Thus, these data do not support the routine prescription of fluoxetine early after stroke in 
order to reduce dependency and disability [29,30]. Clinicians and patients may wish to 
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consider the routine use of fluoxetine early after stroke for its small effects on depression, but 
this would need to be weighed up against the excess of seizures and bone fractures. 
There are some limitations at study and outcome level: only four trials were of high 
methodological quality, not all had been registered prospectively or reported the same 
outcomes.  Furthermore, different scales were used for the same outcome; although we used 
SMD to combine data, the interpretation of SMD is not intuitive, and clinicians prefer to 
know the effect size on a familiar scale (e.g. Functional Independence Measure). Two large 
ongoing trials (AFFINITY and EFFECTS) [31] are using the same measures as FOCUS. A 
future meta-analysis will report mean difference for continuous data. 
We did not register the review in PROSPERO, but we used almost the same methods as the 
2012 Cochrane review. We used sensitive searches developed by Cochrane Stroke, there was 
complete retrieval of identified research, no language restrictions and inclusion of 
unpublished data [12].
About three-quarters of the patients were from the FOCUS trial performed in the National 
Health Service, UK). There was quite marked heterogeneity, even for the high quality trials 
(table 3); this might be explained by the different types of patients and healthcare settings.  
Five of the low quality trials were from China [15, 17, 21, 22, 23]; the three reporting 
disability all found favourable effects of fluoxetine. As the evidence base increases, it may be 
possible to perform meta-regression analyses to determine the factors (such as country, health 
care setting and trial quality) associated with good outcome. 
Ongoing trials will provide information about the external validity of these results in other 
stroke populations with respect to ethnicity, background treatment and healthcare systems.  
AFFINITY [31] is recruiting patients from Vietnam and includes Asian populations. Also, 
further information is needed on other outcomes (e.g. depression, anxiety, cognition, bone 
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fractures, fatigue, health care costs and other potential adverse effects) that are of importance 
to patients, clinicians and policy makers, and to determine whether any benefits or harms at 
the end of treatment persist to the end of follow-up. 
When AFFINITY and EFFECTS are published, we will update the meta-analysis of 
fluoxetine for stroke recovery, and will also perform an individual patient meta-analysis.
Our searches identified several completed trials of other SSRIs in stroke patients with and 
without depression and other mood disorders, which will be included in the next update of the 
Cochrane review of SSRIs for stroke recovery. 
Finally, it would be a significant waste of resources if further trials of fluoxetine in stroke are 
started before ongoing trials have reported and been included in a future meta-analysis [32]. 
FUNDING 
Maree L. Hackett held a National Health and Medical Research Council Career Development 
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Table 1  Characteristics of the randomised controlled trials (RCTs) that are included in this review 
Study Country Participants 
(pathological type and 
time since stroke)
Number 
recruited
Number 
included 
at end of 
treatment 
Dose and 
duration of 
fluoxetine 
Control Outcomes reported 
by the trial authors
Follow-up 
period
Birchenall 
2018 
France Stroke or brain 
haemorrhage, day 3 to 
day 15 
6 (study 
terminated 
early)
6 20mg daily 
for 3 months
Placebo Several clinical and 
TMS measurements, 
death. 
End of 
treatment 
and at month 
6
Chollet 2011 France Ischaemic stroke, 5-10 
days
118 113 20mg daily 
for 3 months
Matching 
placebo
Primary outcome: 
FMMS.  Secondary 
endpoints: NIHSS, 
mRS and MADRS at 
0, 30 and 90 days.  
AEs
End of 
treatment
Dam 1996 Italy Ischaemic stroke, 1-6 
months 
35 33 20mg daily 
for 12 weeks
Matching 
placebo
HDRS, HSS (total, gait 
and motor scores), BI, 
death, AEs 
End of 
treatment
FOCUS 
collaborators 
2018
UK Any stroke, 2-15 days 3127 3106 20mg daily 
for 6 months
Matching 
placebo
Primary: mRS. 
Secondary: SIS, 
depression, MHI5, 
fatigue, Euroquol 5D 
5L, health care costs
End of 
treatment 
and then 6 
months later
He 2004 China First ever stroke, all 
pathological types. 
Mean time 3.1 days in 
fluoxetine and 3.5days  
in control
84 71 20mg daily 
for 8 weeks
Usual stroke 
care
HAMD, SSS. AEs  End of 
treatment
He 2016 China Ischaemic stroke, 
within 1 week
374 350 20mg for 90 
days
Usual care NIHSS, BI; AEs End of 
treatment, 
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and at day 
180
Kong 2006 China Any pathological type, 
within 7 days
90 73 20mg for 8 
weeks
Matching 
placebo
HAMD, BI, NIHSS.
Somatic side effects 
and hyponatraemia
End of 
treatment
Li 2004 China Any pathological type, 
mean time to 
recruitment was 2 days
67 67 20mg daily 
for 4 weeks
Routine 
stroke care
HAMD, CSS; AEs in 
fluoxetine group
End of 
treatment
Marquez-
Romero 
2013
Mexico Intracerebral 
haemorrhage within 10 
days
32 30 20mg daily 
for 90 days
Matching 
placebo
Primary: FMMS, mRS
Secondary: NIHSS, BI, 
AEs
End of 
treatment
Pariente 
2001
France Lacunar ischaemic 
stroke
8 8 Single 20mg 
dose 
Placebo Finger tapping and 
clinical scales 
presented only as 
graphs. fMRI 
activation location
Post-
treatment
Robinson 
2000 (follow 
up reported 
in Mikami 
2011)
USA and 
Argentina
All pathological types, 
within 6 months 
33 28 Dose 
increased 
over 3 weeks 
from 10mg to 
30mg daily; 
total 12 
weeks
Matching 
placebo
HDRS, mRS, FIM, 
MMSE, JHFI, death, 
AEs
End of 
treatment
Shah 2016 India Haemorrhagic stroke, 
5-10 days after onset
89 84 10mg for one 
week, 
increased to 
20mg after 
one week, 
Inert capsule 
‘similar’ to 
fluoxetine
Primary outcome: 
FMMS 
mRS and AEs
End of 
treatment
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total 3 
months
Zhao 2011 China Stroke with aphasia, 
‘early treatment with 
fluoxetine’, precise 
time not stated
82 71 20mg for 12 
weeks 
Standard care MESS, ADL End of 
treatment
ADL: Activities of Daily Living
AE: Adverse Events
BI: Barthel Index
CSS: Chinese Stroke Scale
FIM: Functional Independence Measure
FMMS: Fugl-Meyer Motor Scale
fMRI: functional magnetic resonance imaging
HAMD/HDRS: Hamilton Depression Rating Scale
HSS: Hemispheric Stroke Scale
JHFI: Johns Hopkins Functioning Inventory
MADRS: Montgomery-Åsberg Depression Rating Scale
MMSE: Mini Mental State Examination
MESSS: Modified Edinburgh-Scandinavian Stroke Scale
mRS: modified Rankin Score
MHI5 Mental Health Inventory 5
NIHSS: National Institutes of Health Stroke Scale
SSS: Scandinavian Stroke Scale
SIS: Stroke Impact Scale
TMS: Transmagnetic stimulation
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Table 2 Effects sizes from meta-analysis of primary and secondary outcomes; end of 
treatment; from all trials using fixed effects models, where at least two trials provided data 
that could be included.   
Number of trials 
(number of 
participants) 
contributing to 
the meta-analysis
Effect size (RR or SMD) 
and 95% CI
P value I2
Independent (modified 
Rankin score 0-2)
3 trials (n=3249) RR1.00 (0.91 to 1.09) 0.99 78%
Disability 7 trials (n=3404) SMD 0.05 (-0.02 to 0.12) 0.15 81%
Neurological deficit score 8 trials (n=803) SMD -0.28 (-0.42 to -0.14) <0.0001 77%
Depression-continuous 
data
6 trials (n=3113) SMD -0.16 (-0.23 to -0.09) <0.0001 92%
Depression-dichotomous 2 trials (n=3194) RR 0.77 (0.65 to 0.90) 0.001 53%
Motor score 5 trials (n=3079) SMD 0.06 (-0.02 to 0.13) 0.12 95%
Cognition 2 trials (n=2834) SMD -0.04 (-0.11 to 0.03) 0.32 0%
Death 11 trials (n=3824) RR 1.0 (0.79 to1.26) 1.00 0%
Cognition 2 trials (n=2793) SMD -0.04 (-0.11 to 0.03) 0.3 0%
Seizures 7 trials (n=3815) RR 1.49 (1.05 to 2.11) 0.03 0%
Gastrointestinal symptoms 
(nausea, diarrhoea, 
abdominal pain)
7 trials (n=688) RR 1.38 (0.99 to 1.94) 0.06 8%
Serious bleeding 2 trials (n=3477) RR 1.10 (0.72 to 1.62) 0.67 0%
Leaving before the end of 
first follow-up
11 trials (n=3972) RR 0.92 (0.61 to 1.40) 0.71 0%
RR: relative risk
SMD: standardised mean difference
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Table 3
Summary effect sizes for trials at low risk of bias, at end of treatment, where at least two 
trials reported the outcome of interest. Fixed effects models 
Number of trials 
and participants 
contributing to 
the meta-
analysis 
Effect size P value I2
Independent  (modified 
Rankin score 0-2) 
3 trials (n=3269) RR1.00 (0.91 to 1.09) 0.99 78%
Disability 2 trials (n=2853) SMD -0.01 (-0.09 to 
0.06)
0.75 0%
Neurological deficit 
score
2 trials (n=142) SMD -0.30 (-0.63 to 
0.04)
0.08 0%
Depression (continuous 
data)
2 trials (n=2861) SMD -0.11 (-0.19 to -
0.04)
0.002 69%
Motor score 3 trials (n=2936) SMD 0.02 (-0.05 to 0.09) 0.58 88%
Death 4 trials (n=3260) RR 0.99 (0.79 to 1.25) 0.95 0%
Gastrointestinal  
symptoms
2 trials (n=148) RR 2.19 (1.0 to 4.76) 0.05 0%
Leaving the trial before 
first follow-up
4 trials (n=3283) RR 1.01 (0.48 to 2.10) 0.98 0%
Seizures 3 trials (n=3275) RR 1.47 (0.99 to 2.18) 0.06 0% 
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Objective: To determine whether fluoxetine, at any dose, given within the first year after 
stroke to patients who did not have to have mood disorders at randomisation reduced 
disability, dependency, neurological deficits and fatigue; improved motor function, mood, 
and cognition at the end of treatment and follow-up, with the same number or fewer adverse 
effects. 
Methods: Searches (from 2012) in July 2018 included databases, trials registers, reference 
lists, contact with experts. Co-primary outcomes were dependence and disability. 
Dichotomous data were synthesised using risk ratios (RR) and continuous data using 
standardised mean differences (SMD). Quality was appraised using Cochrane risk of bias 
methods. Sensitivity analyses explored influence of study quality.
Results: The searches identified 3412 references of which 491 full texts were assessed for 
eligibility. Six new completed RCTs (n=3710) were eligible, and were added to the seven 
trials identified in a 2012 Cochrane review (total: 13 trials, n=4145).  There was no difference 
in the proportion independent (3 trials, n=3249, 36.6% fluoxetine vs 36.7% control; RR 1.00, 
95% confidence interval 0.91 to 1.09, p=0.99, I2 78%) nor in disability (7 trials n=3404, SMD 
0.05, -0.02 to 0.12 p=0.15, I2=81%) at end of treatment. Fluoxetine was associated with better 
neurological scores and less depression. Among the four (n=3283) high quality RCTs, the 
only difference between groups was lower depression scores with fluoxetine. 
Conclusion: This class I evidence demonstrates that fluoxetine does not reduce disability and 
dependency after stroke but improves depression. 
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Background and purpose  (word count 240)
Worldwide, stroke is the second leading cause of death, the third leading cause of disability 
[1], and results in 6.5 million years being lived with disability [2].  Fluoxetine is a selective 
serotonin reuptake inhibitor (SSRI) which has been used for many years to treat mood 
disorders, including post-stroke depression. A 2010 systematic review suggested that 
fluoxetine might improve recovery in stroke patients without depression [3]. In 2011, a 
randomised controlled trial (RCT) recruiting 118 patients with hemiparesis due to recent (5-
10 days previously) ischaemic stroke reported better motor recovery and reduced dependency 
with 3 months treatment with fluoxetine [4], possibly by promotion of neurogenesis [5], 
neuroprotection [6], modulation of cerebral motor activity [7] and prevention of depression. 
A 2012 Cochrane systematic review of SSRIs for stroke recovery suggested that fluoxetine 
reduced disability after stroke even in patients without depression, but poor methodological 
trial quality probably introduced bias [8]. In December 2018, one very large (n=3127) trial 
of fluoxetine for stroke recovery was published [9]. Meta-analyses should be updated as soon 
as there are new studies that might change the conclusions of the review. In this paper, we 
report the meta-analysis of fluoxetine for stroke recovery. The Cochrane review of SSRI 
for stroke recovery will be updated subsequently. 
Objective
We sought to determine whether fluoxetine, at any dose, given within the first year after 
stroke to patients who did not have to have mood disorders at randomisation, reduced 
disability, dependency, neurological deficits and fatigue, and improved motor function, 
mood, and cognition at the end of treatment and follow-up, with the same number or fewer 
adverse effects. 
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Methods 
Protocol and registration
We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analysis). Data supporting this review are available from the corresponding author. 
We did not register this review on PROSPERO as we used the same methods as the 2012 
Cochrane review, except for a) including only fluoxetine trials b) excluding trials requiring 
patients to have mood disorders at randomisation, c) simplifying our sensitivity analyses by 
excluding trials at high or unclear risk of bias in at least one domain rather than considering 
each domain individually, d) excluding trials comparing fluoxetine plus another ‘active 
treatment’ versus the ‘active treatment’ and e) defining incomplete outcome data reporting as 
systematic differences in withdrawals between groups rather than a total of >5%. These five 
criteria (a-e) were agreed prior to study selection and data extraction. After study selection 
and data extraction, but prior to analyses, we decided to report the proportion independent 
(modified Rankin score, mRS 0-2) rather than the proportion dependent (mRS 3-5).  
Random effects models had been used in the 2012 Cochrane review because we assumed that 
the included studies would represent a random sample of the effect sizes that could be 
observed. As the large Fluoxetine or Control Under Supervision (FOCUS) trial had 
systematically different results from the smaller trials, a random effects model would have 
given disproportionate weight to smaller studies [10]. Therefore we report fixed effects 
models. We performed sensitivity analyses using random effects models and report any major 
differences between the two. 
Eligibility criteria
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Participants: stroke in the previous year. Stroke was defined as sudden-onset focal 
neurological disturbance, assumed to be vascular in origin, and lasting more than 24 hours 
[11]. We excluded trials requiring patients to have a mood disorder at randomisation.   
Types of intervention: any dose of fluoxetine, any mode of delivery, given for any duration. 
Comparator arm was usual care or a placebo. We excluded studies comparing fluoxetine plus 
another 'active treatment' versus ‘active treatment' alone, because of possible interactions.  
Outcomes We pre-specified two co-primary outcomes: independence or disability at the end 
of treatment (using any measure). Improvements in disability (performance of activities of 
daily living) could be important to patients even without a change in overall dependence.
Secondary outcomes: independence and disability at the end of follow-up. Neurological 
score, depression, anxiety, cognition, quality of life, fatigue, healthcare costs, death, motor 
scores, adverse events (at the end of treatment and/or at the end of follow-up), ‘leaving the 
trial before scheduled follow-up’ which included any reason other than death for missing 
outcome data.  
Report characteristics: We included all reports irrespective of year of publication, language 
and publication status. Where necessary we sought unpublished data from authors.
Information sources
Searches were performed:  
Cochrane Stroke Group Trials Register (17 July 2018); 
* Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2018, 
Issue 6); 
* MEDLINE Ovid (from 1948 to 17 July 2018); 
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* Embase Ovid (from 1980 to 17 July 2018); 
* CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; from 1982 to 
17 July 2018); 
* AMED (Allied and Complementary Medicine; from 1985 to 17 July 2018); 
* PsycINFO Ovid (from 1967 to 17 July 2018). 
* US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov 
(www.clinicaltrials.gov); and * World Health Organization International Clinical Trials 
Registry Platform (apps.who.int/trialsearch) on 26th June 2018. 
We screened reference lists from review articles and included papers. We contacted experts 
to identify additional studies. 
Study selection
Duplicate references were removed using COVIDENCE software (www.covidence.org). 
Titles and abstracts were scrutinised by two authors. Obviously irrelevant articles were 
excluded.
Full texts of potentially relevant articles were retrieved and inclusion criteria applied by two 
authors. A third author was involved if there was disagreement. We included studies meeting 
our criteria.  
Data collection process
Two reviewers independently extracted data from the new trials using COVIDENCE.  We 
contacted the authors if data were missing or required in a different format.  
Data items 
Continuous and dichotomous data were extracted. If trials reported the same number of 
patients at beginning and end, we assumed there had been no deaths. If there was no 
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description of how adverse events were recorded, we included any available data on adverse 
events, but did not assume the absence of serious adverse events unless the authors had 
explicitly reported this.  If there was a different number of patients at the end of the trial, we 
extracted data on deaths and drop-outs for other reasons. The denominator was the number of 
patients for whom a particular outcome was available. 
Risk of bias of individual studies
Two authors using the same criteria as previously [8].  We included allocation (selection 
bias), blinding (performance bias and detection bias), incomplete outcome data (systematic 
differences between groups in withdrawals from a study), selective reporting and other 
potential sources of bias.  
Pre-specified sensitivity analyses 
Sensitivity analyses explored the influence of bias by excluding studies with unclear or high 
risk of bias across one or more key domains [10]. 
Summary measures and synthesis of results
Risk ratios (RRs) were used for dichotomous data and for ordinal scales with an established 
cut-point. Standardised mean differences (SMD) were used for continuous data and ordinal 
scales with no standard cut-point.  We pre-specified our interpretation of SMD: 0.2 represents 
a small effect, 0.5 a moderate effect, and 0.8 a large effect [10]. 
One trial [12] reported medians, interquartile ranges and ranges. We estimated the mean and 
standard deviation (SD) using the best available method [13]. 
Risk of bias across studies
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Funnel plot was used to investigate publication bias. When available, we scrutinised 
protocols to investigate selective reporting. 
Subgroup analyses  
Because fluoxetine may be more effective when given earlier after stroke, we aimed to 
explore the influence of time since stroke at recruitment on our primary outcome by 
categorising studies as less than three months, three to six months, six to nine months, nine to 
12 months.  
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Results
From the database searches, we identified 3412 references, removed 426 duplicates, screened 
2988 references, and assessed 500 full texts for eligibility (figure 1).  Three published papers 
had the same grant number [14-16], very similar inclusion criteria and recruited patients from 
the same hospital during overlapping time periods; one appeared to be the three year follow-
up data [16] from one of the earlier publications [15]. Thus we included the publication with 
the largest number of patients reporting our pre-specified outcomes [15] and categorised the 
other two [14,16] as ‘awaiting assessment’ pending further information. We identified three 
further new eligible trials from the database searches [12, 17, 18] and one by contact with 
experts [19]. We also included FOCUS [9]. 
These six new trials (n=3710) [9, 12, 15, 17-19] were added to seven eligible trials [4, 20-25] 
(n=435) identified in the 2012 Cochrane review (total 13 completed trials, n=4145, table 1). 
One further registered trial was withdrawn because it recruited no patients [27].
Several ongoing RCTs together aim to recruit about 3775 patients (appendix). 
Risk of Bias
There were four high quality trials (n=3283) with a low risk of bias across important quality 
criteria [4, 9,12,18] (figure 2).  One terminated early having recruited 6 patients, and reported 
no deaths [18].  The Funnel plot for disability showed no clear evidence of publication bias 
(available on request).
Results of studies and synthesis of results
Co-primary outcomes: independence and disability at end of treatment (figures 3 and 4). 
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Three trials (n=3249) reported independence. Fixed effects meta-analysis found no difference 
in the proportion independent (36.6% in fluoxetine vs 36.7% control; RR 1.00, 95% 
confidence interval 0.91 to 1.09, p=0.99, I2 78%) and no difference in disability (7 trials 
n=3404, SMD 0.05 (-0.02 to 0.12) p=0.15, I2=81%). 
Two other trials [19, 26] reported improvements in mRS in the fluoxetine group but the data 
were in a format that could not be used in the meta-analysis and the authors did not respond 
to our requests for clarification.  
Random effects models demonstrated a small, but statistically significant benefit of 
fluoxetine on disability (SMD 0.34, 0.04 to 0.64, p=0.03, I2=81%); and a higher RR (RR 1.87 
(0.74 to 4.56; p=0.19, I2=78%) of being independent than the fixed effects models because of 
the greater weight given to smaller positive trials.
Secondary outcomes at end of treatment: summary effect sizes (table 2) 
Fluoxetine was associated with better neurological scores (8 trials, n=803, SMD -0.28 (-0.42 
to -0.14) p=<0.001, I2 77%), better depression scores (6 trials n=3113 SMD -0.16 (-0.23 to -
0.09) p<0.0001, I2 92%), fewer diagnoses of depression (2 trials n=3194 RR 0.77 (0.65 to 
0.90) p=0.001, I2=53%) but more seizures (7 trials n=3815, 3.9% vs 2.6% RR 1.49 (1.05 to 
2.11) p=0.03, I2=0). Random effects models gave broadly similar results. FOCUS identified a 
slight excess of bone fractures in the fluoxetine group which was statistically significant. No 
other trial reported fractures. 
End of follow-up 
Two trials (n=2924) reported disability at end of follow up: SMD was 0.11 (-0.17 to 0.40) 
p=0.45, I2=85% (fixed effects).
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Sensitivity analyses: high quality trials only (table 3), fixed effects 
Fixed effects models found a small, but statistically significant effect on depression scores at 
end of treatment (2 trials, n=2861, -0.11 (-0.19 to -0.04) p=0.002, I2=69%). Random effects 
found a slightly larger effect size for depression which was not statistically significant (-0.23 
(-0.56 to 0.10) p=0.07, I2 61%).
Subgroup analyses
We did not perform subgroup analyses because all trials except two (n=68) recruited patients 
within three months of stroke onset.
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Discussion
This systematic review of fluoxetine for stroke recovery identified 14 trials recruiting more 
than 4000 patients of which four (n=3283) were of high methodological quality. 
There were no differences between groups for the co-primary outcomes of dependency and 
disability. Fluoxetine was associated with better neurological scores at the end of treatment, 
better depression scores and fewer diagnoses of depression, although the effect sizes were all 
small and there was substantial heterogeneity. There was a higher risk of seizures with 
fluoxetine. However, when only high quality trials were considered, the only statistically 
significant difference between groups was better (lower) depression scores at the end of 
treatment.  
We used fixed effect models as these give appropriate weight to larger trials. The sensitivity 
analysis using random effects models found a spuriously large benefit of fluoxetine on 
independence (RR 1.87) because of the disproportionate weight given to smaller trials. Fixed 
and random effect models produced only slightly different effect sizes for depression scores. 
Previous meta-analyses suggested that fluoxetine might reduce dependency and disability if 
given early after stroke [3, 8, 28]. This current meta-analysis, which included many more 
patients than previous reviews, has not confirmed these promising effects. Although one of 
the reviews [28] strongly recommended fluoxetine to promote neurological recovery, this 
recommendation was based on the results of just four reports [4, 14, 15, 22], only one of 
which was high quality [4].   
Thus, these data do not support the routine prescription of fluoxetine early after stroke in 
order to reduce dependency and disability [29,30]. Clinicians and patients may wish to 
consider the routine use of fluoxetine early after stroke for its small effects on depression, but 
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this would need to be weighed up against the excess of seizures and bone fractures. This 
review has not addressed the question about whether fluoxetine is of benefit to stroke 
survivors with mood disorders-this will be addressed by other systematic reviews and 
meta-analyses which are currently being updated. 
There are some limitations at study and outcome level: only four trials were of high 
methodological quality, not all had been registered prospectively or reported the same 
outcomes.  Furthermore, different scales were used for the same outcome; although we used 
SMD to combine data, the interpretation of SMD is not intuitive, and clinicians prefer to 
know the effect size on a familiar scale (e.g. Functional Independence Measure). Two large 
ongoing trials (AFFINITY and EFFECTS) [31] are using the same measures as FOCUS. A 
future meta-analysis will report mean difference for continuous data. 
We did not register the review in PROSPERO, but we used almost the same methods as the 
2012 Cochrane review. We used sensitive searches developed by Cochrane Stroke, there was 
complete retrieval of identified research, no language restrictions and inclusion of 
unpublished data [12].
About three-quarters of the patients were from the FOCUS trial performed in the National 
Health Service, UK). In FOCUS, entry criteria were broad and patients did not have to 
have motor deficits, as in the FLAME trial. However, the subgroup analysis of patients 
with motor deficits recruited to FOCUS found no evidence of an effect on either the 
mRS or motor score of the Stroke Impact Scale. 
There was quite marked heterogeneity, even for the high quality trials (table 3); this might be 
explained by the different types of patients and healthcare settings.  Five of the low quality 
trials were from China [15, 17, 21, 22, 23]; the three reporting disability all found favourable 
effects of fluoxetine. As the evidence base increases, it may be possible to perform meta-
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regression analyses to determine the factors (such as country, health care setting and trial 
quality) associated with good outcome.  We did not pre-specify other outcomes that might 
plausibly be influenced by fluoxetine such as sleep quality and irritability, though we 
noted that the included trials did not measure these outcomes.  
Ongoing trials with a very similar protocol to FOCUS, which have recruited patients 
from different parts of the world, will provide information about the external validity of 
these results in other stroke populations with respect to ethnicity, background treatment and 
healthcare systems.  AFFINITY [31] recruited patients from Vietnam and includes Asian 
populations and EFFECTS recruited from Sweden. Also, further information is needed on 
other outcomes (e.g. depression, anxiety, cognition, bone fractures, fatigue, health care costs 
and other potential adverse effects) that are of importance to patients, clinicians and policy 
makers, and to determine whether any benefits or harms at the end of treatment persist to the 
end of follow-up. 
When AFFINITY and EFFECTS are published, we will update the meta-analysis of 
fluoxetine for stroke recovery, and will also perform an individual patient meta-analysis.
Our searches identified several completed trials of other SSRIs in stroke patients with and 
without depression and other mood disorders, which will be included in the next update of the 
Cochrane review of SSRIs for stroke recovery. 
Finally, before any further trials of fluoxetine for stroke recovery are started/funded, it 
would be prudent to wait for the results of AFFINITY and EFFECTS [32]. 
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Table 1 Characteristics of the randomised controlled trials (RCTs) that are included in this review 
Study Country Participants 
(pathological type and 
time since stroke)
Number 
recruited
Number 
included 
at end of 
treatment 
Dose and 
duration of 
fluoxetine 
Control Outcomes reported 
by the trial authors
Follow-up 
period
Birchenall 
2018 
France Stroke or brain 
haemorrhage, day 3 to 
day 15 
6 (study 
terminated 
early)
6 20mg daily 
for 3 months
Placebo Several clinical and 
TMS measurements, 
death. 
End of 
treatment 
and at month 
6
Chollet 2011 France Ischaemic stroke, 5-10 
days
118 113 20mg daily 
for 3 months
Matching 
placebo
Primary outcome: 
FMMS.  Secondary 
endpoints: NIHSS, 
mRS and MADRS at 
0, 30 and 90 days.  
AEs
End of 
treatment
Dam 1996 Italy Ischaemic stroke, 1-6 
months 
35 33 20mg daily 
for 12 weeks
Matching 
placebo
HDRS, HSS (total, gait 
and motor scores), BI, 
death, AEs 
End of 
treatment
FOCUS 
collaborators 
2018
UK Any stroke, 2-15 days 3127 3106 20mg daily 
for 6 months
Matching 
placebo
Primary: mRS. 
Secondary: SIS, 
depression, MHI5, 
fatigue, Euroquol 5D 
5L, health care costs
End of 
treatment 
and then 6 
months later
He 2004 China First ever stroke, all 
pathological types. 
Mean time 3.1 days in 
fluoxetine and 3.5days  
in control
84 71 20mg daily 
for 8 weeks
Usual stroke 
care
HAMD, SSS. AEs  End of 
treatment
He 2016 China Ischaemic stroke, 
within 1 week
374 350 20mg for 90 
days
Usual care NIHSS, BI; AEs End of 
treatment, 
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and at day 
180
Kong 2006 China Any pathological type, 
within 7 days
90 73 20mg for 8 
weeks
Matching 
placebo
HAMD, BI, NIHSS.
Somatic side effects 
and hyponatraemia
End of 
treatment
Li 2004 China Any pathological type, 
mean time to 
recruitment was 2 days
67 67 20mg daily 
for 4 weeks
Routine 
stroke care
HAMD, CSS; AEs in 
fluoxetine group
End of 
treatment
Marquez-
Romero 
2013
Mexico Intracerebral 
haemorrhage within 10 
days
32 30 20mg daily 
for 90 days
Matching 
placebo
Primary: FMMS, mRS
Secondary: NIHSS, BI, 
AEs
End of 
treatment
Pariente 
2001
France Lacunar ischaemic 
stroke
8 8 Single 20mg 
dose 
Placebo Finger tapping and 
clinical scales 
presented only as 
graphs. fMRI 
activation location
Post-
treatment
Robinson 
2000 (follow 
up reported 
in Mikami 
2011)
USA and 
Argentina
All pathological types, 
within 6 months 
33 28 Dose 
increased 
over 3 weeks 
from 10mg to 
30mg daily; 
total 12 
weeks
Matching 
placebo
HDRS, mRS, FIM, 
MMSE, JHFI, death, 
AEs
End of 
treatment
Shah 2016 India Haemorrhagic stroke, 
5-10 days after onset
89 84 10mg for one 
week, 
increased to 
20mg after 
one week, 
Inert capsule 
‘similar’ to 
fluoxetine
Primary outcome: 
FMMS 
mRS and AEs
End of 
treatment
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total 3 
months
Zhao 2011 China Stroke with aphasia, 
‘early treatment with 
fluoxetine’, precise 
time not stated
82 71 20mg for 12 
weeks 
Standard care MESS, ADL End of 
treatment
ADL: Activities of Daily Living
AE: Adverse Events
BI: Barthel Index
CSS: Chinese Stroke Scale
FIM: Functional Independence Measure
FMMS: Fugl-Meyer Motor Scale
fMRI: functional magnetic resonance imaging
HAMD/HDRS: Hamilton Depression Rating Scale
HSS: Hemispheric Stroke Scale
JHFI: Johns Hopkins Functioning Inventory
MADRS: Montgomery-Åsberg Depression Rating Scale
MMSE: Mini Mental State Examination
MESSS: Modified Edinburgh-Scandinavian Stroke Scale
mRS: modified Rankin Score
MHI5 Mental Health Inventory 5
NIHSS: National Institutes of Health Stroke Scale
SSS: Scandinavian Stroke Scale
SIS: Stroke Impact Scale
TMS: Transmagnetic stimulation
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Table 2 Effects sizes from meta-analysis of primary and secondary outcomes; end of 
treatment; from all trials using fixed effects models, where at least two trials provided data 
that could be included.   
Number of trials 
(number of 
participants) 
contributing to 
the meta-analysis
Effect size (RR or SMD) 
and 95% CI
P value I2
Independent (modified 
Rankin score 0-2)
3 trials (n=3249) RR1.00 (0.91 to 1.09) 0.99 78%
Disability 7 trials (n=3404) SMD 0.05 (-0.02 to 0.12) 0.15 81%
Neurological deficit score 8 trials (n=803) SMD -0.28 (-0.42 to -0.14) <0.0001 77%
Depression-continuous 
data
6 trials (n=3113) SMD -0.16 (-0.23 to -0.09) <0.0001 92%
Depression-dichotomous 2 trials (n=3194) RR 0.77 (0.65 to 0.90) 0.001 53%
Motor score 5 trials (n=3079) SMD 0.06 (-0.02 to 0.13) 0.12 95%
Cognition 2 trials (n=2834) SMD -0.04 (-0.11 to 0.03) 0.32 0%
Death 11 trials (n=3824) RR 1.0 (0.79 to1.26) 1.00 0%
Cognition 2 trials (n=2793) SMD -0.04 (-0.11 to 0.03) 0.3 0%
Seizures 7 trials (n=3815) RR 1.49 (1.05 to 2.11) 0.03 0%
Gastrointestinal symptoms 
(nausea, diarrhoea, 
abdominal pain)
7 trials (n=688) RR 1.38 (0.99 to 1.94) 0.06 8%
Serious bleeding 2 trials (n=3477) RR 1.10 (0.72 to 1.62) 0.67 0%
Leaving before the end of 
first follow-up
11 trials (n=3972) RR 0.92 (0.61 to 1.40) 0.71 0%
RR: relative risk
SMD: standardised mean difference
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Table 3
Summary effect sizes for trials at low risk of bias, at end of treatment, where at least two 
trials reported the outcome of interest. Fixed effects models 
Number of trials 
and participants 
contributing to 
the meta-
analysis 
Effect size P value I2
Independent  (modified 
Rankin score 0-2) 
3 trials (n=3269) RR1.00 (0.91 to 1.09) 0.99 78%
Disability 2 trials (n=2853) SMD -0.01 (-0.09 to 
0.06)
0.75 0%
Neurological deficit 
score
2 trials (n=142) SMD -0.30 (-0.63 to 
0.04)
0.08 0%
Depression (continuous 
data)
2 trials (n=2861) SMD -0.11 (-0.19 to -
0.04)
0.002 69%
Motor score 3 trials (n=2936) SMD 0.02 (-0.05 to 0.09) 0.58 88%
Death 4 trials (n=3260) RR 0.99 (0.79 to 1.25) 0.95 0%
Gastrointestinal  
symptoms
2 trials (n=148) RR 2.19 (1.0 to 4.76) 0.05 0%
Leaving the trial before 
first follow-up
4 trials (n=3283) RR 1.01 (0.48 to 2.10) 0.98 0%
Seizures 3 trials (n=3275) RR 1.47 (0.99 to 2.18) 0.06 0% 
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480 references excluded 
 
150 duplicate reference 
117 review no new trials 
68 commentaries 
30 wrong comparator 
29 wrong study design 
21 wrong patient population 
32 wrong drug 
13 wrong intervention 
6 conference proceedings no new 
trials 
5 old reviews (2011 or earlier) 
4 the trial never started 
2 follow up of original trial 
1 registry Database Link 
1 wrong outcomes 
1 book-no new studies 
Seven new studies included (in 
addition to the six we had 
identified in the 2012 Cochrane 
review)
10 studies ongoing 
3 studies awaiting classification
1 study terminated
One study 
identified by 
contact with 
experts
3413 references imported for 
screening
426 duplicates removed
2988 studies screened 2488 studies irrelevant
500 full-text studies assessed for 
eligibility
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